Saturday 31 October 2026 Export BMY’s income statement to Excel — free account

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

62.55 1.16 +1.89%

Follow BMY

Alert me

Market cap: $125.4B
P/E: 13.8×
Fwd P/E: 11.6×
Dividend yield: 4.03%
F-score: 8/9
Altman Z: 2.14
Beneish M: −2.69
Dividend safety: 63/100

Overview Business Profile Earnings & Analysis Segments Filings

Insider Decisions trades per month

Total sells 2.29

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	1	—	—	—	1	1	—

Insider Ownership 0.10%

Capital & Financial Ratios $m

Market Cap 125,400.00

Revenue 49,186.00

Net Income 9,274.00

Free Cash Flow 11,440.00

Net Debt 32,053.00

Current Ratio 1.53

Debt/Equity 1.93

P/E ratio 13.78

Fwd P/E 11.60

P/S ratio 2.60

P/B ratio 5.72

Past 5Y EPS Growth —

This Y EPS Growth 3.89%

Next Y EPS Growth 3.99%

Next Y revenue growth 3.55%

Next 5Y EPS Growth (4.76%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 9.94%

10-year low 10-year high

P/S against its own 10 years 26.33%

10-year low 10-year high

P/B against its own 10 years 59.13%

10-year low 10-year high

EV/Sales against its own 10 years 27.40%

10-year low 10-year high

EV/FCF against its own 10 years 54.50%

10-year low 10-year high

Dividends

Payout Ratio 0.56

Annual Dividend Rate 2.52

Annual Dividend Yield 4.03%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	2.52	0.63 0.63 0.63 0.63
2025	2.48	0.62 0.62 0.62 0.62
2024	2.40	0.60 0.60 0.60 0.60
2023	2.28	0.57 0.57 0.57 0.57
2022	2.16	0.54 0.54 0.54 0.54
2021	1.47	0.49 0.49 0.49
2020	2.29	0.45 0.45 0.45 0.45 0.49
2019	1.64	0.41 0.41 0.41 0.41
2018	1.60	0.40 0.40 0.40 0.40
2017	1.56	0.39 0.39 0.39 0.39
2016	1.14	0.38 0.38 0.38

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	12,280	10,859	10,673	11,067
Receivables	10,921	10,747	11,414	10,553
Inventory	2,662	2,557	2,690	2,737
Other	5,907	5,617	4,613	4,222
	31,770	29,780	29,390	28,579

	2023	2024	2025	Q'26
Payables	3,259	3,602	3,575	4,158
ST’ Debt	3,119	2,046	2,261	1,027
Other	15,884	18,126	17,581	13,474
	22,262	23,774	23,417	18,659

Compound Annual Growth %

	10y	5y	3y
Sales	11.27%	2.54%	1.45%
Cash Flow	21.00%	0.15%	2.71%
Earnings	16.25%	0.00%	3.69%
Book Value	2.52%	(13.35%)	(15.91%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 1.59 Actual 2.04

1.02 1.31 1.60 1.88 2.17

Q3 FY25 Beat +0.15

Q4 FY25 Beat +0.11

Q1 FY26 Beat +0.14

Q2 FY26 Beat +0.45

Q3 FY26 — Oct 29

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	1.48	1.63	Beat by 0.15
Q4 FY25	1.15	1.26	Beat by 0.11
Q1 FY26	1.44	1.58	Beat by 0.14
Q2 FY26	1.59	2.04	Beat by 0.45
Q3 FY26	1.21	—	Reports 29 October 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.31	1.62	—	—	—
’25	1.20	0.64	1.08	0.53	3.46
’24	(5.89)	0.83	0.60	0.04	(4.41)
’23	1.07	0.99	0.93	0.87	3.86
’22	0.59	0.66	0.75	0.95	2.95
’21	0.89	0.47	0.69	1.07	3.12
’20	(0.34)	(0.04)	0.82	(4.45)	(3.99)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	11,489	12,973	—	—	—
’25	11,201	12,269	12,222	12,502	48,194
’24	11,865	12,201	11,892	12,342	48,300
’23	11,337	11,226	10,966	11,477	45,006
’22	11,648	11,887	11,218	11,406	46,159
’21	11,073	11,703	11,624	11,985	46,385
’20	10,781	10,129	10,540	11,068	42,518

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1,104	3,393	—	—	—
’25	1,954	3,917	6,311	1,974	14,156
’24	2,834	2,326	5,591	4,439	15,190
’23	2,970	1,887	4,751	4,252	13,860
’22	3,812	2,261	3,687	3,306	13,066
’21	3,824	3,060	5,266	4,057	16,207
’20	3,937	4,493	2,267	3,355	14,052

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	757	3,088	—	—	—
’25	1,694	3,556	5,991	1,604	12,845
’24	2,550	2,064	5,267	4,061	13,942
’23	2,692	1,628	4,409	3,922	12,651
’22	3,559	1,989	3,440	2,960	11,948
’21	3,651	2,850	4,996	3,737	15,234
’20	3,751	4,362	2,114	3,072	13,299

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
												Ten-year view		Analyst estimates Powerpack
Price, $
Price, $	Low	49.03	46.01	46.94	42.48	45.76	53.22	60.86	48.25	39.35	42.52		(1.6%)	‡‡‡‡	‡‡‡‡	‡‡‡‡	‡‡‡‡
	High	77.12	66.10	70.05	64.75	68.34	69.75	81.44	75.18	61.08	63.33		(2.2%)	‡‡‡‡	‡‡‡‡	‡‡‡‡	‡‡‡‡
People
People	Employees	25,000	23,700	23,300	30,000	30,250	32,200	34,300	34,100	34,100	32,500		+3.0%	‡‡‡‡	‡‡‡‡	‡‡‡‡	‡‡‡‡
	Revenue/emp, $m	0.78	0.88	0.97	0.87	1.41	1.44	1.35	1.32	1.42	1.48		+7.4%	‡‡‡‡	‡‡‡‡	‡‡‡‡	‡‡‡‡
Income, $m
Income, $m	Revenue	19,427	20,776	22,561	26,145	42,518	46,385	46,159	45,006	48,300	48,194		+10.6%	49,906	48,522	40,941	(5.3%)
	Gross margin, %	74.42	71.05	71.34	69.10	72.31	78.57	78.04	76.24	71.08	71.08		(3.3) pt	Powerpack Bristol Myers Squibb Company’s next three years, line by line Analysts expect revenue to shrink 5.3% a year to 2028 — slower than the 10.6% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	5,915	5,131	5,968	4,975	(6,871)	8,098	7,713	8,440	(8,379)	9,328		+5.2%
	EBT margin, %	30.45	24.70	26.45	19.03	(16.16)	17.46	16.71	18.75	(17.35)	19.36		(11.1) pt
	Net income	4,507	975	4,947	3,460	(8,995)	7,014	6,345	8,040	(8,933)	7,055		+5.1%
	Depreciation	382	789	637	1,746	10,380	10,686	10,276	9,760	9,600	4,011		+29.9%
Per share, $
Per share, $	Revenue	11.63	12.63	13.82	15.33	18.83	20.88	21.67	21.75	23.83	23.69		+8.2%
	Earnings	2.67	0.61	3.03	2.02	(3.99)	3.15	2.97	3.88	(4.41)	3.47		+3.0%
	Cash flow	1.83	3.21	4.33	4.82	6.22	7.30	6.13	6.70	7.49	6.96		+16.0%
	Capex	(0.73)	(0.64)	(0.58)	(0.49)	(0.33)	(0.44)	(0.52)	(0.58)	(0.62)	(0.64)		(1.3%)
	Free cash flow	1.10	2.57	3.74	4.32	5.89	6.86	5.61	6.11	6.88	6.32		+21.4%
	Book value	9.78	7.20	8.65	30.32	16.78	16.21	14.61	14.25	8.08	9.10		(0.8%)
	Shares, m	1,671	1,645	1,633	1,705	2,258	2,221	2,130	2,069	2,027	2,034		+2.2%
Valuation, ×
Valuation, ×	P/E	22.27	100.51	17.16	29.05	0.00	19.79	24.25	13.60	0.00	15.59		24.2
	P/S	5.11	4.85	3.76	4.19	3.29	2.99	3.33	2.43	2.37	2.28		3.5
	P/B	6.08	8.51	6.01	2.12	3.70	3.85	4.95	3.70	7.00	5.93		5.2
	EV/Sales	5.13	4.91	3.70	5.38	4.11	3.58	3.99	3.04	3.18	2.99		4.0
	EV/FCF	54.10	24.17	13.65	19.09	13.15	10.90	15.40	10.80	11.01	11.22		18.3
Cash, $m
Cash, $m	Operating cash flow	3,058	5,275	7,066	8,210	14,052	16,207	13,066	13,860	15,190	14,156		+18.6%
	Capex	(1,215)	(1,055)	(951)	(836)	(753)	(973)	(1,118)	(1,209)	(1,248)	(1,311)		+0.8%
	Free cash flow	1,843	4,220	6,115	7,374	13,299	15,234	11,948	12,651	13,942	12,845		+24.1%
Balance, $m
Balance, $m	Working capital	4,863	5,291	7,062	11,050	11,112	11,394	5,383	9,508	6,006	5,973		+2.3%
	Total debt	6,708	7,962	7,349	46,733	50,676	44,553	39,320	39,772	49,649	45,111		+23.6%
	Net debt	358	1,150	(1,410)	31,340	34,845	27,587	30,067	27,492	38,790	34,438		+66.1%
	Shareholders’ equity	16,347	11,847	14,127	51,698	37,882	36,006	31,118	29,485	16,388	18,506		+1.4%
Returns, %
Returns, %	ROA	13.62	2.99	14.36	4.17	(7.26)	6.14	6.14	8.36	(9.53)	7.72		(5.9) pt
	ROIC	22.13	24.67	29.33	3.74	(5.90)	7.96	7.88	9.26	(9.49)	11.01		(11.1) pt
	ROE	28.97	7.14	37.88	10.45	(20.13)	18.93	18.85	26.48	(39.01)	40.43		+11.5 pt

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Where the money comes from and where it goes Fiscal 2025

Fiscal 2025: revenue by regions, and margins
United States	33,279	69.05%
International	13,828	28.69%
Other	1,087	2.26%
Gross margin		71.08%
Operating margin		19.36%
Pre-tax margin		19.36%

Revenue by segment since 2009

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NVS Novartis AG	$294.9B	24.1×	21.8×	+0.78% (above 0%: growing)	−17.39% (below 0%: shrinking)	−15.53% (below 0%: shrinking)	75.19%	31.77%	Compare
AZN AstraZeneca PLC	$270.5B	27.6×	22.4×	+6.41% (above 0%: growing)	+1.90% (above 0%: growing)	−107.45% (below 0%: shrinking)	83.60%	20.57%	Compare
AMGN Amgen Inc.	$249.1B	28.7×	27.9×	+9.53% (above 0%: growing)	+65.41% (above 0%: growing)	+82.57% (above 0%: growing)	72.04%	34.95%	Compare
GILD Gilead Sciences, Inc.	$205.4B	— (loss-making)	— (loss-making)	+10.18% (above 0%: growing)	n/m	+376.81% (above 0%: growing)	79.76%	(133.21%)	Compare
PFE Pfizer Inc.	$170.7B	40.1×	18.6×	+2.60% (above 0%: growing)	n/m	+125.17% (above 0%: growing)	72.78%	20.38%	Compare
NVO Novo Nordisk A/S	$131.0B	9.8×	—	+4.47% (above 0%: growing)	−18.68% (below 0%: shrinking)	+71.57% (above 0%: growing)	78.21%	34.48%	Compare
BMY Bristol Myers Squibb Company	$125.4B	13.8×	11.6×	+5.74% (above 0%: growing)	+153.13% (above 0%: growing)	−13.16% (below 0%: shrinking)	71.28%	31.50%
SNY Sanofi	$102.8B	23.3×	—	+17.35% (above 0%: growing)	−90.76% (below 0%: shrinking)	−45.06% (below 0%: shrinking)	75.47%	17.48%	Compare
GSK GSK PLC Sponsored ADR	$97.6B	15.4×	14.3×	+5.81% (above 0%: growing)	−69.47% (below 0%: shrinking)	+54.83% (above 0%: growing)	73.05%	5.72%	Compare
Median of peers	$188.0B	24.1×	21.8×	+6.11%	−18.03%	+63.20%	75.33%	20.48%

All 21 Drug Manufacturers General stocks →

Business profile

Updated 29 October 2026

Bristol Myers Squibb is a biopharmaceutical company that discovers, develops, licenses, manufactures and sells prescription medicines for serious diseases. Its work spans cancer, blood disorders, immune diseases, cardiovascular conditions and neuroscience. It sells medicines worldwide, mainly through wholesalers, distributors and specialty pharmacies, while promoting their approved uses to healthcare professionals.

Its products include Opdivo, a cancer medicine used in several tumor types, and Eliquis, an oral medicine used to reduce stroke risk in certain patients and to treat blood clots. Camzyos treats adults with symptomatic obstructive hypertrophic cardiomyopathy, a heart condition; Cobenfy treats schizophrenia in adults. Breyanzi is a cell therapy for certain blood cancers.

Read the full business profile →

From the latest earnings call

Updated 26 October 2026

Chris Boerner said the company raised FY2026 revenue and adjusted EPS guidance after growth-portfolio performance and first-half results.
David Elkins said the company expects higher Eliquis revenue growth and intends to use productivity savings for growth-portfolio investment.

Read the Earnings & Analysis →

Analyst rating changes each firm’s latest, last six months

Firm	Date	Action	Rating	Target
Wells Fargo	Oct 20, 2026	Target cut	Hold	65.00 → 60.00

Largest institutional holders 13F, quarter to 30 June 2026

Held by institutions 81.67%

Held by the ten largest 39.91%

Holder	Shares	Stake	Change
Vanguard	202.27m	9.90%	+2.11m
BlackRock	180.38m	8.83%	+8.70m
State Street	102.41m	5.01%	+3.84m
JPMorgan Chase	71.71m	3.51%	−20.76m
Charles Schwab	67.60m	3.31%	+6.48m
Geode Capital Management	56.44m	2.76%	+1.16m
Norges Bank	36.87m	1.80%	+36.87m
Bank of America	34.05m	1.67%	+1.46m
T. Rowe Price	31.73m	1.55%	+21.46m
UBS	31.72m	1.55%	+1.80m

13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.

Pay and ownership Proxy statement filed 25 March 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	21.88m	16.86m	105.00
2024	18.79m	21.20m	105.00
2022	20.05m	35.06m	123.00
2021	19.78m	16.51m	103.00

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement